Annals of Hepatology
Издатель: Elsevier · ISSN 1665-2681 · 90 статей
- Secondary prophylaxis of SBP in cirrhosis: trimethoprim-sulfamethoxazole vs. ciprofloxacin in a propensity-matched cohort
- Hepatocellular carcinoma in Honduras (2014–2023): nationwide trends in hospital discharges and mortality
- Reply to: Comment on “pancreatic involvement and its prognostic impact in acute-on chronic liver failure”
- Sarcopenia risk in liver transplant candidates: Should artificial intelligence-based body composition analysis be incorporated into pre-transplant assessment?
- Comment on “Modification by cofactors in the impacts of body mass index change on the risk of biliary tract cancers”
- Long-term antiviral therapy sustains HBsAg decline, increases HBV RNA negativity and enhances the proportion of patients achieving functional cure in chronic hepatitis B
- Pragmatism should not eclipse validation in expanded HBV management for Latin America: response
- Pragmatism should not eclipse validation in expanded HBV management for Latin America
- Comment on “Development and validation of the HABIT score: a practical and robust tool to predict hepatic steatosis using HbA1c, BMI, and triglycerides in patients with unexplained elevated liver enzymes”
- Comment on “Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab”
- Toward strengthening translational insights of nonselective β-blockers in cirrhosis-associated hepatocellular carcinoma
- Response to letter to the editor on “Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting”
- Early allograft dysfunction in pediatric liver transplantation: The need to consider transplant indications
- Beyond the impact factor: What readers and authors value in scientific journals
- Comment on “drug-induced liver injury: A real-world pharmacovigilance study using the FDA adverse event reporting system database (2004–2024)”
- Beyond portal pressure reduction: Interpreting the survival benefit of statin add-on therapy in portal hypertension
- Antimicrobial resistance in invasive infections among patients with cirrhosis in Latin America: A multicenter registry
- Endoscopy timing in managing acute esophagogastric variceal bleeding: a multicenter retrospective study
- Portopulmonary hypertension: an integrated approach to diagnosis, risk stratification, and management
- Mapping the preclinical therapeutic landscape of cirrhotic portal hypertension: a systematic evidence map
- Efficacy of non-selective beta blockers in the treatment of acute-on-chronic liver failure: a systematic review and meta-analysis
- Impact of metabolic dysfunction-associated steatotic liver disease on the development of hepatocellular carcinoma after HCV cure
- Recurrence of autoimmune liver diseases after liver transplantation: exploratory analysis of a pooled Latin American cohort
- Global Sociodemographic Disparities in the Severity of Alcohol-Associated Hepatitis
- Reflections on the TransMet Trial
- Anticoagulation in cirrhosis: Indications, drug selection, and disease-modifying potential
- Large esophageal varices predict hepatocellular carcinoma in newly diagnosed cirrhosis: insights from machine learning and propensity score analysis
- Characteristics and outcomes of lean versus non-lean metabolic dysfunction-associated steatohepatitis liver transplant recipients
- High Tumor Burden: A Key Predictor of Poor Short-Term Prognosis after First Variceal Bleeding in Patients with Hepatocellular Carcinoma
- Treatment outcomes in hepatic hydrothorax: A propensity score–matched survival analysis